BOSTON, Aug. 18 /PRNewswire/ — China PharmaHub Corp.
(“PharmaHub”), recently merged with World Wide Relics (OTC Bulletin
WRLC), which will be shortly changing its name to China
PharmaHub Corp, is proud to announce it has signed a cooperation
agreement with Chengdu Yongkon Pharmacy Co. Ltd., (“Yongkon”), a
pharmaceutical company based in Sichuan, with an established sales
network of over 2600 hospitals in China. PharmaHub was
authorized by Yongkon as its appointed agent to identify
pharmaceutical products and medical devices in the U.S. and
negotiate the terms to obtain the rights to sell such products and
devices in China.
Yongkon is an established and GMP certified pharmaceutical
company with focus on the identification, development, manufacture,
sales and distribution of Chinese traditional medicine,
biopharmaceuticals and medical equipment with its focus on
antiviral drugs, bio-engineering drugs and anticancer drugs.
Yongkon manufactures and sells over 90 GMP approved drugs in
China. Its leading product, Xiaojinwan, is a well known Traditional
Chinese Medicine treating breast hyperplasia, thyroid and benign
tumor. Yongkon has a marketing force of over 400 sales
personnel in 34 sales offices in over 31 provinces and cities as
well as in Beijing, Tianjin, Shanghai and Chongqing.
Richard Lui, CEO of PharmaHub, said “We are glad to gain another
capable strategic partner in China. In less than one year of
founding, we have successfully established partnerships with
Research Institute and Government Agencies in China. We have now
taken an important step in the partnership with entrepreneurs.
With the accomplishment of this major milestone, we’ve
successfully created a chain of command in the commercialization of
technologies we identify and bring to China. Yongkon supports
our structure with an established sales and marketing t